|
Feb 5
|
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025
|
|
Feb 4
|
Vanda and AnaptysBio link for generalised pustular psoriasis therapy
|
|
Feb 3
|
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
|